Author

Elaine Waldman

Observed name: ELAINE WALDMAN

Institution: Ionis Pharmaceuticals (United States)

Observed institution: Ionis Pharmaceuticals (United States)

OpenAlex ID: A5021342220

Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk

2025 · Nicholas A. Marston, Brian A. Bergmark, et al. · New England Journal of Medicine · 62

OR27-4 Placebo-Controlled and Open-Label Extension Study of a Novel Hepatic-Targeted Antisense Cimdelirsen (IONIS-GHR-LRx) Under Investigation in Acromegaly Patients

2022 · Sanjay Bhanot, Maria Fleseriu, et al. · Journal of the Endocrine Society · 7

Deficiency of the Lipoprotein Lipase Pathway Modifies the Phenotypic Expression of Genetically Determined Lipoprotein(a)

2026 · Sotirios Tsimikas, Xiaohong Yang, et al. · Journal of Lipid Research

Familial Chylomicronemia Syndrome Is a Natural Model of Lp(a) Deficiency

2026 · Sotirios Tsimikas, Veronica Alexander, et al. · Atherosclerosis

Olezarsen Reduces Routinely Measured Lipase and Amylase in Patients With Severe Hypertriglyceridemia: Pooled Analysis From Core and Core2

2026 · Veronica Alexander, Thomas Prohaska, et al. · Atherosclerosis

1217-OR: ApoC3 Inhibitor Olezarsen Markedly Reduces Triglycerides and Risk of Pancreatitis in Severe Hypertriglyceridemia Patients with Diabetes Mellitus: Insights from CORE-TIMI 72a and CORE2-TIMI 72b

2026 · YU MI KANG, BRIAN BERGMARK, et al. · Diabetes

Works count: 6

Citation count: 69

H-index: 2

I10-index: 1